Indivior PLC Ordinary Shares
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more
Indivior PLC Ordinary Shares (INDV) - Net Assets
Latest net assets as of September 2025: $-207.00 Million USD
Based on the latest financial reports, Indivior PLC Ordinary Shares (INDV) has net assets worth $-207.00 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.42 Billion) and total liabilities ($1.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-207.00 Million |
| % of Total Assets | -14.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | -525.61% |
| 10-Year Change | N/A |
| Growth Volatility | 4762.84 |
Indivior PLC Ordinary Shares - Net Assets Trend (2016–2024)
This chart illustrates how Indivior PLC Ordinary Shares's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Indivior PLC Ordinary Shares (2016–2024)
The table below shows the annual net assets of Indivior PLC Ordinary Shares from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-349.00 Million | -12749.41% |
| 2023-12-31 | $2.76 Million | -94.62% |
| 2022-12-31 | $51.28 Million | -74.69% |
| 2021-12-31 | $202.60 Million | +147.08% |
| 2020-12-31 | $82.00 Million | -60.77% |
| 2019-12-31 | $209.00 Million | +216.67% |
| 2018-12-31 | $66.00 Million | +132.51% |
| 2017-12-31 | $-203.00 Million | +31.19% |
| 2016-12-31 | $-295.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Indivior PLC Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 147.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $62.00 Million | % |
| Other Comprehensive Income | $-46.00 Million | % |
| Other Components | $90.00 Million | % |
| Total Equity | $-348.00 Million | 100.00% |
Indivior PLC Ordinary Shares Competitors by Market Cap
The table below lists competitors of Indivior PLC Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dyne Therapeutics Inc
NASDAQ:DYN
|
$2.89 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
$2.90 Billion |
|
TUI AG
PINK:TUIFF
|
$2.90 Billion |
|
Focuslight Technologies Inc. A
SHG:688167
|
$2.90 Billion |
|
Hannover Re
PINK:HVRRY
|
$2.89 Billion |
|
Red Rock Resorts Inc
NASDAQ:RRR
|
$2.89 Billion |
|
Azimut Holding S.p.A
PINK:AZIHF
|
$2.89 Billion |
|
Jiangsu Wujiang China Eastern Silk Market Co Ltd
SHE:000301
|
$2.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Indivior PLC Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 67,903,984 to -348,000,000, a change of -415,903,984 (-612.5%).
- Net income of 2,000,000 contributed positively to equity growth.
- Share repurchases of 173,000,000 reduced equity.
- New share issuances of 3,000,000 increased equity.
- Other comprehensive income increased equity by 1,275,131,942.
- Other factors decreased equity by 1,523,035,926.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.00 Million | +0.57% |
| Share Repurchases | $173.00 Million | -49.71% |
| Share Issuances | $3.00 Million | +0.86% |
| Other Comprehensive Income | $1.28 Billion | +366.42% |
| Other Changes | $-1.52 Billion | -437.65% |
| Total Change | $- | -612.49% |
Book Value vs Market Value Analysis
This analysis compares Indivior PLC Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-1.98 | $31.33 | x |
| 2017-12-31 | $-1.36 | $31.33 | x |
| 2018-12-31 | $0.44 | $31.33 | x |
| 2019-12-31 | $1.38 | $31.33 | x |
| 2020-12-31 | $0.56 | $31.33 | x |
| 2021-12-31 | $1.31 | $31.33 | x |
| 2022-12-31 | $0.37 | $31.33 | x |
| 2023-12-31 | $0.48 | $31.33 | x |
| 2024-12-31 | $-2.62 | $31.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Indivior PLC Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.17%
- • Asset Turnover: 0.90x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (30.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 3.31% | 0.80x | 0.00x | $61.55 Million |
| 2017 | 0.00% | 5.31% | 0.80x | 0.00x | $81.22 Million |
| 2018 | 397.98% | 27.36% | 0.62x | 23.44x | $256.07 Million |
| 2019 | 66.58% | 17.07% | 0.49x | 7.90x | $118.25 Million |
| 2020 | -192.39% | -22.87% | 0.45x | 18.67x | $-165.96 Million |
| 2021 | 101.18% | 26.37% | 0.43x | 9.02x | $184.74 Million |
| 2022 | -101.49% | -5.88% | 0.50x | 34.69x | $-57.16 Million |
| 2023 | 2.95% | 0.18% | 0.56x | 28.78x | $-4.79 Million |
| 2024 | 0.00% | 0.17% | 0.90x | 0.00x | $36.80 Million |
Industry Comparison
This section compares Indivior PLC Ordinary Shares's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Indivior PLC Ordinary Shares (INDV) | $-207.00 Million | 0.00% | N/A | $2.89 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |